MyFinsight
Home
Blog
About
Loss on debt
extinguishment
-$25,232K
(-40.73%↓ Y/Y)
Accrued expenses and
other liabilities
$25,077K
(234.24%↑ Y/Y)
Accounts payable
$23,261K
(1308.36%↑ Y/Y)
Stock-based compensation
expense
$22,219K
(-48.31%↓ Y/Y)
Depreciation and
amortization
$6,538K
(-51.40%↓ Y/Y)
Non-cash operating lease
expense
$1,439K
(-50.99%↓ Y/Y)
Prepaid expenses and
other current assets
-$895K
(-139.51%↓ Y/Y)
Amortization of debt
discounts
$299K
(-96.92%↓ Y/Y)
Net cash provided by
(used in) operating...
$28,477K
(218.41%↑ Y/Y)
Canceled cashflow
$76,483K
Net increase
(decrease) in cash, cash...
-$130,645K
(-119.96%↓ Y/Y)
Canceled cashflow
$28,477K
something is missing
$10,342K
Sale of marketable
securities
$1,874K
Proceeds from the 2026
term loan, net of...
$393,500K
Proceeds from share
purchases under employee...
$2,937K
Proceeds from exercise of
stock options
$741K
(-71.76%↓ Y/Y)
Supplies
$48,309K
(1743.15%↑ Y/Y)
Accounts receivable
$26,372K
(171.20%↑ Y/Y)
Other assets
$924K
(376.65%↑ Y/Y)
Net loss
-$637K
(99.63%↑ Y/Y)
Other
$241K
(119.58%↑ Y/Y)
Net cash used in
investing activities
-$122,192K
(-2898.58%↓ Y/Y)
Net cash provided by
(used in) financing...
-$36,903K
(-105.41%↓ Y/Y)
Canceled cashflow
$12,216K
Canceled cashflow
$397,178K
Effect of exchange rate
changes on cash, cash...
-$27K
(-127.84%↓ Y/Y)
Purchases of marketable
securities
$101,991K
Capitalized software and
purchases of property and...
$32,417K
Repayment of the 2023 term
loan
$406,307K
Repurchase of common stock
$21,361K
(96995.45%↑ Y/Y)
Payment of taxes
withheld from net...
$5,264K
(217.49%↑ Y/Y)
Payment of third-party
debt issuance costs
$1,107K
Payments made on finance
lease obligations
$42K
(-4.55%↓ Y/Y)
Back
Back
Cash Flow
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)
source: myfinsight.com